ODM 208

Drug Profile

ODM 208

Alternative Names: ODM-208

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Class Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action Cholesterol-Side-Chain-Cleavage-Enzyme-Iinhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 08 Sep 2017 Preclinical trials in Prostate cancer in Finland (PO)
  • 08 Sep 2017 Orion plans a phase I trial for castration resistant prostate cancer in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top